Kling Douglas F 4
4 · NewAmsterdam Pharma Co N.V. · Filed Jul 17, 2025
Insider Transaction Report
Form 4
Kling Douglas F
Chief Operating Officer
Transactions
- Sale
Ordinary Shares
2025-07-15$21.38/sh−44,025$941,255→ 47,544 total - Exercise/Conversion
Option (right to buy)
2025-07-16−51,043→ 162,702 totalExercise: $10.90Exp: 2033-01-01→ Ordinary Shares (51,043 underlying) - Exercise/Conversion
Ordinary Shares
2025-07-15$10.90/sh+47,569$518,502→ 91,569 total - Sale
Ordinary Shares
2025-07-15$22.12/sh−3,544$78,393→ 44,000 total - Exercise/Conversion
Ordinary Shares
2025-07-16$10.90/sh+51,043$556,369→ 95,043 total - Sale
Ordinary Shares
2025-07-16$21.10/sh−51,043$1,077,007→ 44,000 total - Exercise/Conversion
Option (right to buy)
2025-07-15−47,569→ 213,745 totalExercise: $10.90Exp: 2033-01-01→ Ordinary Shares (47,569 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F5]The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.